Literature DB >> 15600321

Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques.

Juan C Frias1, Kevin Jon Williams, Edward A Fisher, Zahi A Fayad.   

Abstract

A new contrast agent for MRI based on recombinant HDL-like nanoparticles has been prepared. It shows a great potential as a contrast agent for atherosclerotic plaques in a relative short time (24 h post-injection) as it is selective for the plaques and is an endogenous molecule. It also can distinguish between different types of plaques as the enhancement obtained is different, depending on plaque composition.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15600321     DOI： 10.1021/ja044911a

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN： 0002-7863            Impact factor:   15.419


  94 in total

Review 1.  Emerging applications of nanotechnology for the diagnosis and management of vulnerable atherosclerotic plaques.

Authors:  Shann S Yu; Ryan A Ortega; Brendan W Reagan; John A McPherson; Hak-Joon Sung; Todd D Giorgio
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-08-10

Review 2.  High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.

Authors:  Rui Kuai; Dan Li; Y Eugene Chen; James J Moon; Anna Schwendeman
Journal:  ACS Nano       Date:  2016-02-25       Impact factor: 15.881

3.  Identification of interleukin-2 for imaging atherosclerotic inflammation.

Authors:  Zahi A Fayad; Vardan Amirbekian; Jean-François Toussaint; Valentin Fuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-02       Impact factor: 9.236

Review 4.  Molecular imaging by MRI.

Authors:  Patrick M Winter; Shelton D Caruthers; Samuel A Wickline; Gregory M Lanza
Journal:  Curr Cardiol Rep       Date:  2006-02       Impact factor: 2.931

Review 5.  Advances in detection and characterization of atherosclerosis using contrast agents targeting the macrophage.

Authors:  Michael J Lipinski; Juan Carlos Frias; Zahi A Fayad
Journal:  J Nucl Cardiol       Date:  2006-09       Impact factor: 5.952

Review 6.  Advances in gadolinium-based MRI contrast agent designs for monitoring biological processes in vivo.

Authors:  Jacques Lux; A Dean Sherry
Journal:  Curr Opin Chem Biol       Date:  2018-05-09       Impact factor: 8.822

7.  Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.

Authors:  Jie Tang; Rui Kuai; Wenmin Yuan; Lindsey Drake; James J Moon; Anna Schwendeman
Journal:  Nanomedicine       Date:  2017-04-18       Impact factor: 5.307

8.  Molecular MRI of Atherosclerotic Plaque With Targeted Contrast Agents.

Authors:  David E Sosnovik; Peter Caravan
Journal:  Curr Cardiovasc Imaging Rep       Date:  2009-04-01

9.  Conquering the dark side: colloidal iron oxide nanoparticles.

Authors:  Angana Senpan; Shelton D Caruthers; Ilsu Rhee; Nicholas A Mauro; Dipanjan Pan; Grace Hu; Michael J Scott; Ralph W Fuhrhop; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza
Journal:  ACS Nano       Date:  2009-12-22       Impact factor: 15.881

Review 10.  Modified natural nanoparticles as contrast agents for medical imaging.

Authors:  David P Cormode; Peter A Jarzyna; Willem J M Mulder; Zahi A Fayad
Journal:  Adv Drug Deliv Rev       Date:  2009-11-06       Impact factor: 15.470
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.